Yahoo
KOSDAQ - Delayed Quote KRW

OliX Pharmaceuticals, Inc (226950.KQ)

93,500.00 -500.00 (-0.53%)
At close: 3:30:12 PM GMT+9
Chart Range Bar
Loading chart for 226950.KQ
  • Previous Close 94,000.00
  • Open 94,000.00
  • Bid 93,500.00 x --
  • Ask 93,700.00 x --
  • Day's Range 90,600.00 - 95,900.00
  • 52 Week Range 84,300.00 - 217,000.00
  • Volume 181,807
  • Avg. Volume 249,044
  • Market Cap (intraday) 2.127T
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.

www.olixpharma.com

81

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

226950.KQ
33.40%
KOSPI Composite Index (^KS11)
39.03%

1-Year Return

226950.KQ
21.10%
KOSPI Composite Index (^KS11)
42.64%

3-Year Return

226950.KQ
580.00%
KOSPI Composite Index (^KS11)
150.05%

5-Year Return

226950.KQ
138.52%
KOSPI Composite Index (^KS11)
94.43%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -102.89%

  • Return on Assets (ttm)

    -14.83%

  • Return on Equity (ttm)

    -10.76%

  • Revenue (ttm)

    13.64B

  • Net Income Avi to Common (ttm)

    -14.03B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    214.15B

  • Total Debt/Equity (mrq)

    8.77%

  • Levered Free Cash Flow (ttm)

    -12.63B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: